UA110310C2 - Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar) - Google Patents

Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)

Info

Publication number
UA110310C2
UA110310C2 UAA201500426A UAA201500426A UA110310C2 UA 110310 C2 UA110310 C2 UA 110310C2 UA A201500426 A UAA201500426 A UA A201500426A UA A201500426 A UAA201500426 A UA A201500426A UA 110310 C2 UA110310 C2 UA 110310C2
Authority
UA
Ukraine
Prior art keywords
compounds
lpar
aryl triazole
antagonists
receptors
Prior art date
Application number
UAA201500426A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Стівен Дімс Гебріель
Метью Майкл Гамільтон
Імінь Цянь
Ачютарао Сіддурі
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA110310(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA110310C2 publication Critical patent/UA110310C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA201500426A 2012-06-20 2013-06-17 Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar) UA110310C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661953P 2012-06-20 2012-06-20
PCT/EP2013/062463 WO2013189865A1 (en) 2012-06-20 2013-06-17 N-aryltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
UA110310C2 true UA110310C2 (uk) 2015-12-10

Family

ID=48628669

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201500426A UA110310C2 (uk) 2012-06-20 2013-06-17 Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)

Country Status (22)

Country Link
US (1) US20150133512A1 (fa)
EP (1) EP2864301A1 (fa)
JP (1) JP2015520203A (fa)
KR (1) KR20150011389A (fa)
CN (1) CN104395299A (fa)
AU (1) AU2013279513A1 (fa)
BR (1) BR112014030674A2 (fa)
CA (1) CA2869564A1 (fa)
CL (1) CL2014003241A1 (fa)
CO (1) CO7131357A2 (fa)
EA (1) EA201492281A1 (fa)
HK (1) HK1206339A1 (fa)
IL (1) IL236087A0 (fa)
IN (1) IN2014DN09352A (fa)
MA (1) MA37762B1 (fa)
MX (1) MX2014014711A (fa)
PE (1) PE20142305A1 (fa)
PH (1) PH12014502363A1 (fa)
SG (1) SG11201407228PA (fa)
UA (1) UA110310C2 (fa)
WO (1) WO2013189865A1 (fa)
ZA (1) ZA201408167B (fa)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140067048A (ko) 2011-08-15 2014-06-03 인터뮨, 인크. 라이소포스파티드산 수용체 길항제
WO2014113485A1 (en) * 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
MX382748B (es) 2013-03-15 2025-03-13 Epigen Biosciences Inc Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
KR102433588B1 (ko) 2014-06-27 2022-08-19 우베 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN107827829A (zh) * 2017-11-07 2018-03-23 大连理工大学 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法
CN107721984A (zh) * 2017-11-07 2018-02-23 大连理工大学 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法
KR102725744B1 (ko) 2017-12-19 2024-11-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
BR112020011953A2 (pt) 2017-12-19 2020-11-17 Bristol-Myers Squibb Company ácidos carbamoil ciclo-hexílicos n-ligados a pirazol como antagonistas de lpa
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
JP7256807B2 (ja) * 2017-12-19 2023-04-12 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
EP3728223B1 (en) 2017-12-19 2022-12-28 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
EP3728210A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
KR102828422B1 (ko) 2017-12-19 2025-07-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 이속사졸 아진
US11319315B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2020060914A1 (en) 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Oxabicyclo acids as lpa antagonists
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN111434653A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
KR102775995B1 (ko) 2019-11-15 2025-03-11 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
JP7591066B2 (ja) 2020-06-03 2024-11-27 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
JP7691522B2 (ja) 2021-05-13 2025-06-11 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
CA3238094A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
PE20140879A1 (es) * 2010-12-07 2014-08-06 Amira Pharmaceuticals Inc Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
KR20140067048A (ko) * 2011-08-15 2014-06-03 인터뮨, 인크. 라이소포스파티드산 수용체 길항제
US9321738B2 (en) * 2012-06-20 2016-04-26 Hoffman-La Roche Inc. N-alkyltriazole compounds as LPAR antagonists

Also Published As

Publication number Publication date
CN104395299A (zh) 2015-03-04
KR20150011389A (ko) 2015-01-30
AU2013279513A1 (en) 2014-10-16
US20150133512A1 (en) 2015-05-14
MX2014014711A (es) 2015-03-04
PE20142305A1 (es) 2015-01-16
HK1206339A1 (en) 2016-01-08
BR112014030674A2 (pt) 2017-06-27
CL2014003241A1 (es) 2015-03-20
EP2864301A1 (en) 2015-04-29
PH12014502363A1 (en) 2015-01-12
CO7131357A2 (es) 2014-12-01
CA2869564A1 (en) 2013-12-27
JP2015520203A (ja) 2015-07-16
IL236087A0 (en) 2015-02-01
WO2013189865A1 (en) 2013-12-27
MA37762A1 (fr) 2017-07-31
ZA201408167B (en) 2015-12-23
IN2014DN09352A (fa) 2015-07-17
SG11201407228PA (en) 2014-12-30
EA201492281A1 (ru) 2015-04-30
MA37762B1 (fr) 2018-04-30

Similar Documents

Publication Publication Date Title
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
UA109867C2 (ru) Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar)
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX354102B (es) Derivados de bencimidazol-prolina.
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
IN2014DN06869A (fa)
UA117154C2 (uk) Антагоністи s1p3
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2015002755A3 (en) Compounds for the treatment of malaria
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
WO2014147636A8 (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
TN2011000588A1 (en) Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl) pyridine and their therapeutical uses